Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00078234 | Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 25 | Genta IncorporatedINDUSTRY | 1 | Nov 7, 2011 | clinicaltrials |
| NCT00038623 | Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma | completed | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 2, 2011 | clinicaltrials |
| NCT00452374 | Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL | completed | Phase 1 / Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 2, 2011 | clinicaltrials |
| NCT01003054 | Autologous Transplantation for Chronic Myelogenous Leukemia | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 2, 2011 | clinicaltrials |
| NCT00281476 | The Effect of High Dose Simvastatine on Multiple Myeloma | completed | Phase 1 / Phase 2 | 10 | Vejle HospitalOTHER | 0 | Nov 1, 2011 | clinicaltrials |
| NCT00073489 | A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 23 | Astellas Pharma IncINDUSTRY | 1 | Oct 17, 2011 | clinicaltrials |
| NCT00051597 | A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies | completed | Phase 1 / Phase 2 | 70 | Seagen Inc.INDUSTRY | 1 | Oct 12, 2011 | clinicaltrials |
| NCT00930605 | The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)(C+CHOP/ESHAP) | completed | Phase 2 | 16 | King Chulalongkorn Memorial HospitalOTHER | 1 | Oct 6, 2011 | clinicaltrials |
| NCT00763763 | Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive(AFR07) | completed | Phase 2 | 55 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 5, 2011 | clinicaltrials |
| NCT00250042 | A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec | completed | Phase 2 | 6 | New Mexico Cancer Research AllianceOTHER | 1 | Sep 20, 2011 | clinicaltrials |
| NCT00388531 | Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma | completed | Phase 2 | 10 | PETHEMA FoundationOTHER | 1 | Sep 19, 2011 | clinicaltrials |
| NCT00504634 | Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma | completed | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 15, 2011 | clinicaltrials |
| NCT00791947 | A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT | completed | Phase 2 | 166 | University of AarhusOTHER | 3 | Sep 8, 2011 | clinicaltrials |
| NCT00113932 | UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma | completed | Phase 2 | 140 | University of ArkansasOTHER | 1 | Sep 2, 2011 | clinicaltrials |
| NCT00504803 | Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease | completed | Phase 2 | 30 | University of LiegeOTHER | 1 | Sep 2, 2011 | clinicaltrials |
| NCT00693927 | Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells (PBSC) | completed | Phase 2 | 54 | University of LiegeOTHER | 1 | Sep 2, 2011 | clinicaltrials |
| NCT00004908 | Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma | completed | Phase 2 | — | Northwestern UniversityOTHER | 1 | Aug 26, 2011 | clinicaltrials |
| NCT01423032 | Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 / Phase 3 | 96 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 1 | Aug 25, 2011 | clinicaltrials |
| NCT00760084 | Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 10 | Eisai Inc.INDUSTRY | 1 | Aug 8, 2011 | clinicaltrials |
| NCT00263484 | Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma(dtZ) | completed | Phase 2 | 56 | Gleneagles HospitalOTHER | 3 | Jul 21, 2011 | clinicaltrials |
| NCT00089037 | Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 15, 2011 | clinicaltrials |
| NCT01385891 | Clove In The Treatment Of Relapsed Or Resistant Acute Leukemia In Children(CLOVE) | completed | Phase 2 / Phase 3 | 40 | Istituto Giannina GasliniOTHER | 1 | Jul 8, 2011 | clinicaltrials |
| NCT00275431 | Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies | completed | Phase 2 | 50 | Ascenta TherapeuticsINDUSTRY | 1 | Jun 29, 2011 | clinicaltrials |
| NCT00142129 | Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia | completed | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 27, 2011 | clinicaltrials |
| NCT00165295 | Sildenafil Citrate in Waldenstrom's Macroglobulinemia | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 27, 2011 | clinicaltrials |
| NCT00004084 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia | completed | Phase 1 / Phase 2 | 21 | Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyOTHER | 1 | Jun 22, 2011 | clinicaltrials |
| NCT00004107 | Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia | completed | Phase 1 / Phase 2 | 18 | Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyOTHER | 1 | Jun 22, 2011 | clinicaltrials |
| NCT00561743 | A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients | completed | Phase 2 | 50 | Janssen-Ortho Inc., CanadaINDUSTRY | 0 | Jun 21, 2011 | clinicaltrials |
| NCT00283439 | A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma | completed | Phase 1 / Phase 2 | 39 | AmgenINDUSTRY | 0 | Jun 20, 2011 | clinicaltrials |
| NCT00002681 | Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma | completed | Phase 1 / Phase 2 | 25 | Roger Williams Medical CenterOTHER | 1 | Jun 10, 2011 | clinicaltrials |
| NCT01010880 | Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 16 | Biokine Therapeutics LtdINDUSTRY | 1 | Jun 10, 2011 | clinicaltrials |
| NCT01370434 | Two Cycles of PAD Combination by AHCT in MM(PADinMM) | completed | Phase 2 | 43 | Cooperative Study Group A for HematologyNETWORK | 1 | Jun 10, 2011 | clinicaltrials |
| NCT00270049 | Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia | completed | Phase 2 | 195 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
| NCT00042822 | FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 17, 2011 | clinicaltrials |
| NCT00216697 | An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy | completed | Phase 2 | 13 | Janssen Pharmaceutical K.K.INDUSTRY | 0 | May 17, 2011 | clinicaltrials |
| NCT00752518 | A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 35 | Janssen Pharmaceutical K.K.INDUSTRY | 0 | May 17, 2011 | clinicaltrials |
| NCT00806767 | Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer | completed | Phase 2 | 82 | Institut Paoli-CalmettesOTHER | 1 | May 17, 2011 | clinicaltrials |
| NCT00840684 | Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 135 | Institut Paoli-CalmettesOTHER | 1 | May 13, 2011 | clinicaltrials |
| NCT00002504 | Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer | completed | Phase 2 | — | Hoag Memorial Hospital PresbyterianOTHER | 1 | May 12, 2011 | clinicaltrials |
| NCT00049413 | Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma | completed | Phase 2 | — | Hoag Memorial Hospital PresbyterianOTHER | 1 | May 12, 2011 | clinicaltrials |
| NCT00559624 | Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients | completed | Phase 1 / Phase 2 | 40 | Advancell - Advanced In Vitro Cell Technologies, S.A.INDUSTRY | 3 | May 10, 2011 | clinicaltrials |
| NCT00621400 | Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis | completed | Phase 1 / Phase 2 | 27 | Nantes University HospitalOTHER | 1 | May 10, 2011 | clinicaltrials |
| NCT00339196 | 5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS | completed | Phase 2 | 25 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 9, 2011 | clinicaltrials |
| NCT00193505 | Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00193518 | Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 41 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT01341262 | THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM) | completed | Phase 2 | 378 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 0 | Apr 25, 2011 | clinicaltrials |
| NCT00101647 | Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia | completed | Phase 2 | 197 | Bristol-Myers SquibbINDUSTRY | 23 | Apr 15, 2011 | clinicaltrials |
| NCT00101595 | Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | completed | Phase 2 | 96 | Bristol-Myers SquibbINDUSTRY | 20 | Apr 14, 2011 | clinicaltrials |
| NCT00337454 | Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan | completed | Phase 1 / Phase 2 | 48 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 14, 2011 | clinicaltrials |
| NCT00400673 | A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia | completed | Phase 2 | 581 | Northern Italy Leukemia GroupOTHER | 1 | Apr 1, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Nov 7, 2011source: clinicaltrials